insurance changes for glp-1 drugs to glp 1 CMS Issues Coverage Guidance on Anti-Obesity Upcoming Insurance Changes GLP-1 – Costly GLP-1 Drugs are Rarely

10.1016/S0022-3476(88)80180-X J

Active Proliferative Conditions: Research should not be conducted in subjects with active cancer or other proliferative diseases, given IGF-1s growth-promoting effects

Polymers 15 (17), 3539

At ACR Convergence 2025, researchers from Toronto and NYU reported that PsA patients starting GLP-1 receptor agonists had significant improvements in joint counts, CRP, pain scores, and DAPSA disease activity scores within one year of treatment. Whats interesting is that you dont seem to need a large dose to see these benefits

Symptoms that warrant a visit include noticeable bulges in the abdomen or groin, pain or discomfort in those areas, and any associated nausea or vomiting